Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.

Liu F, Wu L, Wu G, Wang C, Zhang L, Tomlinson S, Qin X.

Atherosclerosis. 2014 May;234(1):237-43. doi: 10.1016/j.atherosclerosis.2014.03.004. Epub 2014 Mar 15.

2.
3.
4.

Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.

Zhu P, Bailey SR, Lei B, Paulos CM, Atkinson C, Tomlinson S.

Transplantation. 2017 Apr;101(4):e75-e85. doi: 10.1097/TP.0000000000001625.

PMID:
28045880
5.

The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.

Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.

Arthritis Rheum. 2011 Apr;63(4):1076-85. doi: 10.1002/art.30222.

6.

A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor.

Qiu S, Liu N, Jia L, Yang G, Su W, Li J, Song L, Yang C, Wang J, Zhang C, Wang Z, Qiao F, Tomlinson S, Atkinson C, Sun Y, Huang L, Song H, Wang Y, Li Z.

Virol J. 2012 Nov 23;9:285. doi: 10.1186/1743-422X-9-285.

7.

Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.

Liu F, Sahoo R, Ge X, Wu L, Ghosh P, Qin X, Halperin JA.

J Diabetes Complications. 2017 Feb;31(2):311-317. doi: 10.1016/j.jdiacomp.2016.08.021. Epub 2016 Aug 28.

PMID:
27729184
8.

Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy.

Marshall KM, He S, Zhong Z, Atkinson C, Tomlinson S.

J Exp Med. 2014 Aug 25;211(9):1793-805. doi: 10.1084/jem.20131902. Epub 2014 Aug 11.

9.

Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.

Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S.

J Clin Invest. 2005 Sep;115(9):2444-53. Epub 2005 Aug 25.

10.

Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.

Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X.

Circ Res. 2009 Feb 27;104(4):550-8. doi: 10.1161/CIRCRESAHA.108.191361. Epub 2009 Jan 8.

11.

A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor.

Zhang C, Xu Y, Jia L, Yang Y, Wang Y, Sun Y, Huang L, Qiao F, Tomlinson S, Liu X, Zhou Y, Song H.

Virol J. 2010 Feb 9;7:30. doi: 10.1186/1743-422X-7-30.

12.
13.

Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma.

Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S.

Am J Pathol. 2006 Sep;169(3):1039-47.

14.

Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation.

Atkinson C, He S, Morris K, Qiao F, Casey S, Goddard M, Tomlinson S.

J Immunol. 2010 Dec 1;185(11):7007-13. doi: 10.4049/jimmunol.1001504. Epub 2010 Oct 20.

15.

Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Hu X, Tomlinson S, Barnum SR.

Neurosci Lett. 2012 Nov 30;531(1):35-9. doi: 10.1016/j.neulet.2012.10.012. Epub 2012 Oct 16.

16.

Molecular mechanism of inhibitory effects of CD59 gene on atherosclerosis in ApoE (-/-) mice.

Li B, Xu YJ, Chu XM, Gao MH, Wang XH, Nie SM, Yang F, Lv CY.

Immunol Lett. 2013 Nov-Dec;156(1-2):68-81. doi: 10.1016/j.imlet.2013.09.025. Epub 2013 Sep 29.

PMID:
24084445
17.

Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis.

Mühlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE.

Kidney Int. 2004 Apr;65(4):1214-23.

18.
19.

Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.

Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ.

J Am Soc Nephrol. 2003 Mar;14(3):670-9.

20.

New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.

Schnabolk G, Beon MK, Tomlinson S, Rohrer B.

J Ocul Pharmacol Ther. 2017 Jun;33(5):400-411. doi: 10.1089/jop.2016.0101. Epub 2017 Mar 23.

PMID:
28333572

Supplemental Content

Support Center